immatics Biotechnologies GmbH

Immatics combines the discovery of true targets for cancer immunotherapies with the development of the right T cell receptors with the goal of enabling a robust and specific T cell response against these targets. This deep know-how is the foundation for our pipeline of Adoptive Cell Therapies and TCR Bispecifics as well as our partnerships with global leaders in the pharmaceutical industry. We are committed to delivering the power of T cells and to unlocking new avenues for patients in their fight against cancer.

QUICK FACTS

>250 Team members in Tuebingen and Munich, Germany and Houston, Texas >200 Targets covering major solid tumors - 2 proprietary technology platforms, XPRESIDENT® and XCEPTOR® - 7 proprietary drug discovery programs; 3 of which are in clinical development - Multiple partnered programs